Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.61 |
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | STAT1 | P42224 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 7/20 | 0.51 |
| ▸ | RAB9A | P51151 | 7/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | CASP1 | P29466 | 2/20 | 0.51 |
| ▸ | CASP7 | P55210 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30098950 | 0.81 | KDM4E (0.59) | KMT2AMAPTALDH1A1MEN1KDM4E | |
| SCHEMBL4526983 | 0.80 | NPC1 (0.67) | KMT2AMAPTALDH1A1MEN1KDM4E | |
| SCHEMBL4508303 | 0.80 | MEN1 (0.55) | KMT2AMAPTALDH1A1MEN1KDM4E | |
| SCHEMBL9868243 | 0.76 | MAPT (0.50) | KMT2AMAPTALDH1A1KDM4EGAA | |
| SCHEMBL10277579 | 0.74 | KDM4E (0.64) | KMT2AMAPTALDH1A1MEN1KDM4E | |
| SCHEMBL22658186 | 0.74 | ADRA2A (0.52) | KMT2AMAPTALDH1A1MEN1KDM4E | |
| SCHEMBL13159758 | 0.73 | NPC1 (0.48) | KMT2AMEN1KDM4EL3MBTL1NPC1 | |
| SCHEMBL725810 | 0.72 | ALDH1A1 (0.75) | KMT2AMAPTALDH1A1KDM4EGAA | |
| SCHEMBL30394760 | 0.72 | NPC1 (0.67) | KMT2AMAPTALDH1A1MEN1KDM4E | |
| SCHEMBL4523419 | 0.70 | SMARCA2 (0.56) | KMT2AALDH1A1SMN1; SMN2TP53HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112946157-B | Application of fluorescent thiourea derivatization reagent in detection of 3-chloro-1, 2-propanediol | 武汉轻工大学 | 2023-10-27 | — | — | CN | claimed |
| CN-112946157-A | Application of fluorescent thiourea derivatization reagent in 3-chloro-1, 2-propanediol detection | 武汉轻工大学 | 2021-06-11 | — | — | CN | claimed |
| CN-112946157-B | Application of fluorescent thiourea derivatization reagent in detection of 3-chloro-1, 2-propanediol | 武汉轻工大学 | 2023-10-27 | — | — | CN | disclosed |
| CN-112946157-A | Application of fluorescent thiourea derivatization reagent in 3-chloro-1, 2-propanediol detection | 武汉轻工大学 | 2021-06-11 | — | — | CN | disclosed |
| US-20170216282-A1 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders | GALDERMA LABORATORIES INC | 2017-08-03 | — | — | US | disclosed |
| US-20160220565-A1 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders | Galderma Laboratories, L.P. (US) | 2016-08-04 | — | — | US | disclosed |
| CN-102743380-B | Be used for the treatment of or prevent the compound of rosacea, preparation and method | GALDERMA PHARMA SA (CH) | 2015-08-12 | — | — | CN | disclosed |
| US-20150202202-A1 | COMPOUNDS, FORMULATIONS, AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY SKIN DISORDERS | Galderma Laboratories, L.P. (US) | 2015-07-23 | — | — | US | disclosed |
| CN-104490884-A | Compounds, Formulations, And Methods For Treating Or Preventing Rosacea | GALDERMA PHARMA SA | 2015-04-08 | — | — | CN | disclosed |
| US-8993571-B2 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders | Galderma Laboratories, L.P. (US) | 2015-03-31 | — | — | US | disclosed |
| EP-2815748-A1 | Compounds, formulations, and methods for treating or preventing rosacea | Galderma Pharma S.A. (CH) | 2014-12-24 | — | — | EP | disclosed |
| EP-1761266-A2 | COMPOUNDS, FORMULATIONS, AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY SKIN DISORDERS | Sansrosa Pharmaceutical Development, Inc. (US) | 2007-03-14 | — | — | EP | disclosed |
| US-20060264515-A1 | Compounds, formulations, and methods for ameliorating telangiectasias | SANSROSA PHARMACEUTICAL DEVELOPMENTS, INC. | 2006-11-23 | — | — | US | disclosed |
| CN-1829518-A | Compounds, formulations and methods for treating or preventing rosacea | SANSROSA PHARMACEUTICAL DEV IN (US) | 2006-09-06 | — | — | CN | disclosed |
| US-20060171974-A1 | Compounds, formulations, and methods for treating or preventing rosacea | GALDERMA LABORATORIES INC. | 2006-08-03 | — | — | US | disclosed |
| EP-1631293-A2 | COMPOUNDS, FORMULATIONS, AND METHODS FOR TREATING OR PREVENTING ROSACEA | Sansrosa Pharmaceutical Development, Inc. (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20050276830-A1 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders | GALDERMA LABORATORIES INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005115395-A2 | COMPOUNDS, FORMULATIONS, AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY SKIN DISORDERS | SANSROSA PHARMACEUTICAL DEVELOPMENT, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| WO-2004105703-A2 | COMPOUNDS, FORMULATIONS, AND METHODS FOR TREATING OR PREVENTING ROSACEA | SANSROSA PHARMACEUTICAL DEVELOPMENT, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040242588-A1 | Compounds, formulations, and methods for treating or preventing rosacea | Galderma Holding SA (CH) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060171974-A1 | Compounds, formulations, and methods for treating or preventing rosacea | HRH1, HRH2, HRH4 | KMT2A 1996/4885MAPT 3188/4885ALDH1A1 38/4885 |
| US-20150202202-A1 | COMPOUNDS, FORMULATIONS, AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY SKIN DISORDERS | HRH4, HRH1, HRH3 | KMT2A 3373/4885MAPT 3016/4885ALDH1A1 279/4885 |
| US-20170216282-A1 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders | HRH4, HRH1, HRH3 | KMT2A 3373/4885MAPT 3016/4885ALDH1A1 279/4885 |
| US-20050276830-A1 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders | HRH4, HRH1, HRH3 | KMT2A 3373/4885MAPT 3016/4885ALDH1A1 279/4885 |
| US-20160220565-A1 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders | HRH4, HRH1, HRH3 | KMT2A 3373/4885MAPT 3016/4885ALDH1A1 279/4885 |
| US-20040242588-A1 | Compounds, formulations, and methods for treating or preventing rosacea | HRH1, HRH2, CYP8B1 | KMT2A 1944/4885MAPT 2869/4885ALDH1A1 38/4885 |
| US-20060264515-A1 | Compounds, formulations, and methods for ameliorating telangiectasias | ADRA2B, TEK, ADRB1 | KMT2A 3602/4885MAPT 3951/4885ALDH1A1 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.